Literature DB >> 23192657

Role of prostaglandin receptor EP2 in the regulations of cancer cell proliferation, invasion, and inflammation.

Jianxiong Jiang1, Ray Dingledine.   

Abstract

Population studies, preclinical, and clinical trials suggest a role for cyclooxygenase-2 (COX-2, PTGS2) in tumor formation and progression. The downstream prostanoid receptor signaling pathways involved in tumorigenesis are poorly understood, although prostaglandin E2 (PGE(2)), a major COX-2 metabolite which is usually upregulated in the involved tissues, presumably plays important roles in tumor biology. Taking advantage of our recently identified novel selective antagonist for the EP2 (PTGER2) subtype of PGE(2) receptor, we demonstrated that EP2 receptor activation could promote prostate cancer cell growth and invasion in vitro, accompanied by upregulation of the tumor-promoting inflammatory cytokines, such as IL-1β and IL-6. Our results suggest the involvement of prostaglandin receptor EP2 in cancer cell proliferation and invasion possibly via its inflammatory actions, and indicate that selective blockade of the PGE(2)-EP2 signaling pathway via small molecule antagonists might represent a novel therapy for tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23192657      PMCID: PMC3558819          DOI: 10.1124/jpet.112.200444

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  51 in total

1.  Expression of cyclooxygenase-2 (COX-2) in hepatocellular carcinoma and growth inhibition of hepatoma cell lines by a COX-2 inhibitor, NS-398.

Authors:  S H Bae; E S Jung; Y M Park; B S Kim; B K Kim; D G Kim; W S Ryu
Journal:  Clin Cancer Res       Date:  2001-05       Impact factor: 12.531

Review 2.  Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2.

Authors:  R A Gupta; R N Dubois
Journal:  Nat Rev Cancer       Date:  2001-10       Impact factor: 60.716

3.  Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta 716) knockout mice.

Authors:  M Sonoshita; K Takaku; N Sasaki; Y Sugimoto; F Ushikubi; S Narumiya; M Oshima; M M Taketo
Journal:  Nat Med       Date:  2001-09       Impact factor: 53.440

4.  IL-1 is required for tumor invasiveness and angiogenesis.

Authors:  Elena Voronov; Dror S Shouval; Yakov Krelin; Emanuela Cagnano; Daniel Benharroch; Yoichiro Iwakura; Charles A Dinarello; Ron N Apte
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-21       Impact factor: 11.205

5.  Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor.

Authors:  Li Yang; Noboru Yamagata; Rajwardhan Yadav; Suzanne Brandon; Regina L Courtney; Jason D Morrow; Yu Shyr; Mark Boothby; Sebastian Joyce; David P Carbone; Richard M Breyer
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

6.  Small molecule antagonist reveals seizure-induced mediation of neuronal injury by prostaglandin E2 receptor subtype EP2.

Authors:  Jianxiong Jiang; Thota Ganesh; Yuhong Du; Yi Quan; Geidy Serrano; Min Qui; Iris Speigel; Asheebo Rojas; Nadia Lelutiu; Raymond Dingledine
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-08       Impact factor: 11.205

7.  The alteration of prostaglandin E2 levels in patients with brain tumors before and after tumor removal.

Authors:  Joon-Khim Loh; Shiuh-Lin Hwang; Ann-Shung Lieu; Tzuu-Yuan Huang; Shen-Long Howng
Journal:  J Neurooncol       Date:  2002-04       Impact factor: 4.130

8.  Enhancement of colon carcinogenesis by prostaglandin E2 administration.

Authors:  Toshihiko Kawamori; Naoaki Uchiya; Takashi Sugimura; Keiji Wakabayashi
Journal:  Carcinogenesis       Date:  2003-05       Impact factor: 4.944

9.  Proinflammatory cytokine IL-1 beta promotes tumor growth of Lewis lung carcinoma by induction of angiogenic factors: in vivo analysis of tumor-stromal interaction.

Authors:  Yasuo Saijo; Masashi Tanaka; Makoto Miki; Kazuhiro Usui; Takuji Suzuki; Makoto Maemondo; Xin Hong; Ryushi Tazawa; Toshiaki Kikuchi; Kouji Matsushima; Toshihiro Nukiwa
Journal:  J Immunol       Date:  2002-07-01       Impact factor: 5.422

Review 10.  Cyclooxygenase 2: a molecular target for cancer prevention and treatment.

Authors:  Kotha Subbaramaiah; Andrew J Dannenberg
Journal:  Trends Pharmacol Sci       Date:  2003-02       Impact factor: 14.819

View more
  51 in total

Review 1.  Defining the therapeutic time window for suppressing the inflammatory prostaglandin E2 signaling after status epilepticus.

Authors:  Yifeng Du; Timothy Kemper; Jiange Qiu; Jianxiong Jiang
Journal:  Expert Rev Neurother       Date:  2016-01-13       Impact factor: 4.618

Review 2.  Prostaglandin E2 Signaling: Alternative Target for Glioblastoma?

Authors:  Jianxiong Jiang; Jiange Qiu; Qianqian Li; Zhi Shi
Journal:  Trends Cancer       Date:  2017-01-11

3.  Small-molecule inhibition of prostaglandin E receptor 2 impairs cyclooxygenase-associated malignant glioma growth.

Authors:  Jiange Qiu; Qianqian Li; Katherine A Bell; Xue Yao; Yifeng Du; Erik Zhang; Jane J Yu; Ying Yu; Zhi Shi; Jianxiong Jiang
Journal:  Br J Pharmacol       Date:  2019-04-29       Impact factor: 8.739

4.  Suppressing pro-inflammatory prostaglandin signaling attenuates excitotoxicity-associated neuronal inflammation and injury.

Authors:  Jianxiong Jiang; Ying Yu; Erika Reime Kinjo; Yifeng Du; Hoang Phuong Nguyen; Ray Dingledine
Journal:  Neuropharmacology       Date:  2019-02-11       Impact factor: 5.250

5.  Intracellular EP2 prostanoid receptor promotes cancer-related phenotypes in PC3 cells.

Authors:  Ana Belén Fernández-Martínez; Javier Lucio-Cazaña
Journal:  Cell Mol Life Sci       Date:  2015-04-01       Impact factor: 9.261

Review 6.  The Treatment Landscape and New Opportunities of Molecular Targeted Therapies in Gastroenteropancreatic Neuroendocrine Tumors.

Authors:  Fabiola Amair-Pinedo; Ignacio Matos; Tamara Saurí; Jorge Hernando; Jaume Capdevila
Journal:  Target Oncol       Date:  2017-12       Impact factor: 4.493

Review 7.  Cyclooxygenase-2 in glioblastoma multiforme.

Authors:  Jiange Qiu; Zhi Shi; Jianxiong Jiang
Journal:  Drug Discov Today       Date:  2016-09-28       Impact factor: 7.851

8.  Assessment of the in vitro toxicity of calixarenes and a metal-seamed calixarene: a chemical pathway for clinical application.

Authors:  Arnab Dawn; Xue Yao; Ying Yu; Jianxiong Jiang; Harshita Kumari
Journal:  Supramol Chem       Date:  2019-05-13       Impact factor: 1.688

9.  Rostral Ventrolateral Medulla EP3 Receptor Mediates the Sympathoexcitatory and Pressor Effects of Prostaglandin E2 in Conscious Rats.

Authors:  Samar Rezq; Abdel A Abdel-Rahman
Journal:  J Pharmacol Exp Ther       Date:  2016-08-29       Impact factor: 4.030

10.  Development of second generation EP2 antagonists with high selectivity.

Authors:  Thota Ganesh; Jianxiong Jiang; Ray Dingledine
Journal:  Eur J Med Chem       Date:  2014-06-03       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.